Literature DB >> 10597281

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

D Chauhan1, T Hideshima, P Pandey, S Treon, G Teoh, N Raje, S Rosen, N Krett, H Husson, S Avraham, S Kharbanda, K C Anderson.   

Abstract

Related Adhesion Focal Tyrosine Kinase (RAFTK; also known as Pyk2), is a member of the Focal Adhesion Kinase (FAK) subfamily and is activated by TNF alpha, UV light and increases in intracellular calcium levels. However, the function of RAFTK remains largely unknown. Our previous studies demonstrated that treatment with dexamethasone (Dex), ionizing radiation (IR), and anti-Fas mAb induces apoptosis in multiple myeloma (MM) cells. In the present study, we examined the potential role of RAFTK during induction of apoptosis in human MM cells triggered by these three stimuli. Dex-induced apoptosis, in contrast to apoptosis triggered by anti-Fas mAb or IR, is associated with activation of RAFTK. Transient overexpression of RAFTK wild type (RAFTK WT) induces apoptosis, whereas transient overexpression of Kinase inactive RAFTK (RAFTK K-M) blocks Dex-induced apoptosis. In contrast, transient overexpression of RAFTK K-M has no effect on apoptosis triggered by IR or Fas. In Dex-resistant cells, Dex does not trigger either RAFTK activation or apoptosis. Finally, interleukin-6 (IL-6), a known survival factor for MM cells, inhibits both activation of RAFTK and apoptosis of MM.1S cells triggered by Dex. Our studies therefore demonstrate Dex-induced RAFTK-dependent, and IR or Fas induced RAFTK-independent apoptotic signaling cascades in MM cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597281     DOI: 10.1038/sj.onc.1203082

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

Review 1.  Multiple myeloma.

Authors:  N Raje; K C Anderson
Journal:  Curr Treat Options Oncol       Date:  2000-04

Review 2.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

3.  The nonreceptor protein tyrosine kinase Pyk2 promotes the turnover of monocytes at steady state.

Authors:  Ryan A Llewellyn; Keena S Thomas; Michael F Gutknecht; Amy H Bouton
Journal:  J Leukoc Biol       Date:  2017-07-28       Impact factor: 4.962

4.  Signaling through a novel domain of gp130 mediates cell proliferation and activation of Hck and Erk kinases.

Authors:  M Schaeffer; M Schneiderbauer; S Weidler; R Tavares; M Warmuth; G de Vos; M Hallek
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis.

Authors:  Rachel Spokoini; Shlomit Kfir-Erenfeld; Eitan Yefenof; Ronit Vogt Sionov
Journal:  Mol Endocrinol       Date:  2010-04-06

6.  Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.

Authors:  C J Wu; X F Yang; S McLaughlin; D Neuberg; C Canning; B Stein; E P Alyea; R J Soiffer; G Dranoff; J Ritz
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

7.  Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Authors:  M B Meads; B Fang; L Mathews; J Gemmer; L Nong; I Rosado-Lopez; T Nguyen; J E Ring; W Matsui; A R MacLeod; J A Pachter; L A Hazlehurst; J M Koomen; K H Shain
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

8.  Pyk2 promotes tumor progression in multiple myeloma.

Authors:  Yu Zhang; Michele Moschetta; Daisy Huynh; Yu-Tzu Tai; Yong Zhang; Wenjing Zhang; Yuji Mishima; Jennifer E Ring; Winnie F Tam; Qunli Xu; Patricia Maiso; Michaela Reagan; Ilyas Sahin; Antonio Sacco; Salomon Manier; Yosra Aljawai; Siobhan Glavey; Nikhil C Munshi; Kenneth C Anderson; Jonathan Pachter; Aldo M Roccaro; Irene M Ghobrial
Journal:  Blood       Date:  2014-09-12       Impact factor: 22.113

9.  Differential effects of Pyk2 and FAK on the hypertrophic response of cardiac myocytes.

Authors:  Emmanuel B Menashi; Joseph C Loftus
Journal:  Cell Tissue Res       Date:  2009-05-12       Impact factor: 5.249

10.  Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.

Authors:  Peter M Voorhees; Qing Chen; George W Small; Deborah J Kuhn; Sally A Hunsucker; Jeffrey A Nemeth; Robert Z Orlowski
Journal:  Br J Haematol       Date:  2008-03-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.